Natural Products Canada

CEO Shelley King leads the executive team that makes deployment decisions, supported by regional directors covering British Columbia, the Prairies, Ontario, Québec, and Atlantic Canada. The firm's model relies on a commercialization programs director and a member-engagement team to vet candidates, rather than a traditional investment committee. No external investment board is disclosed.

NPC builds its pipeline through six regional directors embedded across Canada, who identify bio-based startups in agriculture, cleantech, foodtech, personal care, and biomaterials. The firm also draws from its 4,000-member community of corporate partners, industry experts, and investors who refer technologies. This geography-dispersed, sector-specific model gives it early visibility into university spinouts and government-lab innovations before they reach institutional venture desks.

The firm only engages in direct, non-dilutive capital placements to individual startups. There is no public record of NPC committing capital to third-party venture funds, participating in LP positions, or managing a fund-of-funds program. Its entire model is built around putting capital and advisory resources directly into early-stage bioeconomy companies.

NPC targets the pre-seed and seed readiness stage — often before a company has taken any institutional venture funding. The firm explicitly positions its up-to-$350,000 Smart Capital as a derisking injection meant to help a technology become investable for later-stage investors. Portfolio companies like Aux Labs and Opalia received NPC support at the earliest stages of their commercial development.